Rhiniseng
inactivated vaccine to prevent progressive and non-progressive atrophic rhinitis in pigs
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Rhiniseng
|
Agency product number |
EMEA/V/C/000160
|
Active substance |
|
International non-proprietary name (INN) or common name |
inactivated vaccine to prevent progressive and non-progressive atrophic rhinitis in pigs
|
Species |
Pigs (gilts and sows)
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AB04
|
Publication details | |
---|---|
Marketing-authorisation holder |
Laboratorios Hipra S.A.
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
15/09/2010
|
Contact address |
Avda. La Selva, 135 |
Product information
09/11/2018 Rhiniseng - EMEA/V/C/000160 - IB/0008
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella-bronchiseptica and Pasteurella-multocida infections during the fattening period.
Challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.